{
    "clinical_study": {
        "@rank": "1676", 
        "acronym": "Vacyless\u00ae", 
        "arm_group": [
            {
                "arm_group_label": "Vacyless\u00ae 1000 mg", 
                "arm_group_type": "Experimental", 
                "description": "one Vacyless\u00ae 1000 mg tablets, 3 times daily for 7days"
            }, 
            {
                "arm_group_label": "Vacyless\u00ae 500mg", 
                "arm_group_type": "Experimental", 
                "description": "Two Vacyless\u00ae 500mg tablets, 3 times daily for 7 days"
            }, 
            {
                "arm_group_label": "Valtrex\u00ae 500 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Two Valtrex\u00ae 500 mg tablets, 3 times daily for 7days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the safety and efficacy of Vacyless\u00ae and Valtrex\u00ae in\n      patients with acute herpes zoster."
        }, 
        "brief_title": "A Study of Vacyless\u00ae Versus Valtrex\u00ae in Patients With Herpes Zoster", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Herpes Zoster", 
        "condition_browse": {
            "mesh_term": "Herpes Zoster"
        }, 
        "detailed_description": {
            "textblock": "Primary Endpoint:\n\n      - Lesion assessment - Rash severity, in terms of rash counts\n\n      Secondary Endpoints:\n\n        -  Pain assessment\n\n        -  Clinical global impression\n\n        -  Safety information of valacyclovir"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women between 20 to 80 years of age.\n\n          -  Patients with a clinical diagnosis of HZ as evidenced by a unilateral dermatomal\n             rash.\n\n          -  Patients with zoster-related rash (rash severity is greater than or equal to  mild).\n\n          -  Patients are able to be enrolled into the study 72 hours from appearance of rash (for\n             example, lesions or vesicles).\n\n          -  Patients provided written informed consent.\n\n          -  Patients who are able to complete all study visits per protocol.\n\n          -  Men and premenopausal women must agree to practice a barrier method of birth control\n             or  the use of a spermicide for one month after the last dose of study drug (oral\n             contraceptives are not permitted). Subject should be withdrew from the study if\n             contraceptions are faild.\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant or lactating.\n\n          -  Patients with multidermatomal or disseminated HZ (greater than 20 lesions beyond the\n             dermatomes adjacent to the primarily involved dermatome).\n\n          -  Patients with HZ ophthalmicus, defined as cutaneous lesions in the dermatome\n             associated with the ophthalmic division of the trigeminal nerve\n\n          -  Patients with history of impaired renal function, (e.g., calculated creatinine\n             clearance  less than 50 mL/min/1.73 m2)\n\n          -  Patients are taking narcotic analgesic routinely for a chronic pain condition\n\n          -  Patients are taking tricyclic antidepressants\n\n          -  Patients who received systemic antivirals with activity against VZV within the past\n             30 days, or a topical antiviral to treat their current HZ\n\n          -  Patients with immunosuppressive or immunodeficient condition resulting from:\n\n        disease (e.g.,  HIV) corticosteroid use (except intermittent or topical/inhaled\n        beclomethasone dipropionate or equivalent < 800 mcg/day), or other\n        immunosuppressive/cytotoxic therapy (cancer chemotherapy or organ transplantation )\n\n          -  Patients with any other condition (e.g., extensive psoriasis, chronic pain syndrome,\n             cognitive impairment) that, in the opinion of the site investigator, might interfere\n             with the evaluations required by the study\n\n          -  Patients who are not ambulatory (bed-ridden or homebound); hospitalized patients may\n             be enrolled if they are ambulatory and able to complete the study requirements\n\n          -  Patients with history of allergy to valacyclovir hydrochloride and acetaminophen\n\n          -  Patients are unlikely to adhere to protocol follow-up"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152800", 
            "org_study_id": "YSP-RCH3002P02"
        }, 
        "intervention": {
            "arm_group_label": [
                "Vacyless\u00ae 1000 mg", 
                "Vacyless\u00ae 500mg", 
                "Valtrex\u00ae 500 mg"
            ], 
            "intervention_name": "valacyclovir hydrocholoride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Valacyclovir"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Taichung", 
                    "country": "Taiwan"
                }, 
                "name": "Taichung Veterans General Hospital"
            }
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Study of Vacyless\u00ae Versus Valtrex\u00ae in Patients With Herpes Zoster", 
        "overall_official": {
            "affiliation": "Taichung Veterans General Hospital", 
            "last_name": "Zhi-Yuan Shi, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Taiwan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "the rash severity, in terms of rash counts", 
            "safety_issue": "No", 
            "time_frame": "Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152800"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "VAS Pain score", 
            "safety_issue": "Yes", 
            "time_frame": "Day 28"
        }, 
        "source": "Yung Shin Pharm. Ind. Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yung Shin Pharm. Ind. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}